JP2024525610A5 - - Google Patents

Info

Publication number
JP2024525610A5
JP2024525610A5 JP2024500477A JP2024500477A JP2024525610A5 JP 2024525610 A5 JP2024525610 A5 JP 2024525610A5 JP 2024500477 A JP2024500477 A JP 2024500477A JP 2024500477 A JP2024500477 A JP 2024500477A JP 2024525610 A5 JP2024525610 A5 JP 2024525610A5
Authority
JP
Japan
Application number
JP2024500477A
Other languages
Japanese (ja)
Other versions
JP2024525610A (ja
JPWO2023283614A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073528 external-priority patent/WO2023283614A2/en
Publication of JP2024525610A publication Critical patent/JP2024525610A/ja
Publication of JP2024525610A5 publication Critical patent/JP2024525610A5/ja
Publication of JPWO2023283614A5 publication Critical patent/JPWO2023283614A5/ja
Pending legal-status Critical Current

Links

JP2024500477A 2021-07-09 2022-07-08 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 Pending JP2024525610A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163219977P 2021-07-09 2021-07-09
US63/219,977 2021-07-09
PCT/US2022/073528 WO2023283614A2 (en) 2021-07-09 2022-07-08 Muscle targeting complexes and uses thereof for treating dystrophinopathies

Publications (3)

Publication Number Publication Date
JP2024525610A JP2024525610A (ja) 2024-07-12
JP2024525610A5 true JP2024525610A5 (https=) 2025-07-17
JPWO2023283614A5 JPWO2023283614A5 (https=) 2025-07-17

Family

ID=84802085

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500477A Pending JP2024525610A (ja) 2021-07-09 2022-07-08 筋標的化複合体およびジストロフィノパチーを処置するためのその使用

Country Status (10)

Country Link
US (1) US20240209119A1 (https=)
EP (1) EP4367247A4 (https=)
JP (1) JP2024525610A (https=)
KR (1) KR20240035823A (https=)
CN (1) CN118510898A (https=)
AU (1) AU2022307934A1 (https=)
CA (1) CA3226298A1 (https=)
IL (1) IL309909A (https=)
MX (1) MX2024000490A (https=)
WO (1) WO2023283614A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
IL309936A (en) 2021-07-09 2024-03-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of dystrophinopathy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20250339553A1 (en) 2022-04-15 2025-11-06 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
CN118546927B (zh) * 2024-05-29 2025-02-25 广东省农业科学院动物科学研究所 一种靶向敲低鸡SRSF2基因表达的siRNA及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008317566B2 (en) * 2007-10-26 2014-05-01 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP3829595A4 (en) * 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
KR20230044242A (ko) * 2020-07-23 2023-04-03 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도

Similar Documents

Publication Publication Date Title
JP2024525610A5 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13150U (https=)
BY13135U (https=)
BY13137U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13149U (https=)
CN307046922S (https=)